NO20042209L - Fremgangsmater og anordninger for fremstilling av proteiner med forutbestemte post-translasjonelle modifikasjoner - Google Patents
Fremgangsmater og anordninger for fremstilling av proteiner med forutbestemte post-translasjonelle modifikasjonerInfo
- Publication number
- NO20042209L NO20042209L NO20042209A NO20042209A NO20042209L NO 20042209 L NO20042209 L NO 20042209L NO 20042209 A NO20042209 A NO 20042209A NO 20042209 A NO20042209 A NO 20042209A NO 20042209 L NO20042209 L NO 20042209L
- Authority
- NO
- Norway
- Prior art keywords
- translational modifications
- post
- mammalian cells
- predetermined post
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/NL2001/000792 WO2003050286A1 (en) | 2001-10-29 | 2001-10-29 | Methods and means for producing proteins with predetermined post-translational modifications |
PCT/NL2002/000257 WO2003089468A1 (en) | 2002-04-19 | 2002-04-19 | Methods and means for producing proteins with predetermined post-translational modifications |
PCT/NL2002/000686 WO2003038100A1 (en) | 2001-10-29 | 2002-10-29 | Methods and means for producing proteins with predetermined post-translational modifications |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20042209L true NO20042209L (no) | 2004-07-28 |
Family
ID=26642018
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20042209A NO20042209L (no) | 2001-10-29 | 2004-05-28 | Fremgangsmater og anordninger for fremstilling av proteiner med forutbestemte post-translasjonelle modifikasjoner |
Country Status (14)
Country | Link |
---|---|
US (3) | US7304031B2 (no) |
EP (2) | EP2292770B1 (no) |
JP (1) | JP4583029B2 (no) |
CN (1) | CN100347306C (no) |
AT (1) | ATE542904T1 (no) |
AU (1) | AU2002335585B2 (no) |
BR (1) | BR0213402A (no) |
CA (2) | CA2465007C (no) |
DK (1) | DK1440157T3 (no) |
EA (2) | EA008220B1 (no) |
ES (1) | ES2381104T3 (no) |
IL (3) | IL161674A (no) |
NO (1) | NO20042209L (no) |
WO (1) | WO2003038100A1 (no) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4051416B2 (ja) | 1995-06-15 | 2008-02-27 | クルーセル ホランド ベスローテン フェンノートシャップ | 遺伝子治療に使用されるヒト組換えアデノウイルス用のパッケージングシステム |
US7604960B2 (en) | 1999-04-15 | 2009-10-20 | Crucell Holland B.V. | Transient protein expression methods |
US7297680B2 (en) * | 1999-04-15 | 2007-11-20 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
US20050164386A1 (en) * | 1999-04-15 | 2005-07-28 | Uytdehaag Alphonsus G. | Overexpression of enzymes involved in post-translational protein modifications in human cells |
US8236561B2 (en) | 1999-04-15 | 2012-08-07 | Crucell Holland B.V. | Efficient production of IgA in recombinant mammalian cells |
US6855544B1 (en) | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
US7192759B1 (en) | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
US7527961B2 (en) | 1999-11-26 | 2009-05-05 | Crucell Holland B.V. | Production of vaccines |
US7521220B2 (en) | 1999-11-26 | 2009-04-21 | Crucell Holland B.V. | Production of vaccines |
US7767643B2 (en) | 2000-12-29 | 2010-08-03 | The Kenneth S. Warren Institute, Inc. | Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
US20030072737A1 (en) | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
BR0213402A (pt) * | 2001-10-29 | 2004-10-13 | Crucell Holland Bv | Métodos para identificar uma célula de mamìfero capaz de produzir uma molécula proteinácea, para selecionar uma célula de mamìfero capaz de produzir uma molécula proteinácea, para se obter uma célula de mamìfero a partir de uma população heterogênea de células, e para produzir uma molécula proteinácea, composição farmaceuticamente aceitável, eritropoietina recombinantemente produzida, usos de uma célula de mamìfero, da eritropoietina recombinantemente produzida, e de uma composição de moléculas semelhantes à eritropoietina, preparação farmacêutica, método para o tratamento preventivo e/ou terapêutico de um distúrbio, composição de moléculas semelhates à eritropoietina, métodos para produzir, em uma célula de mamìfero, moléculas proteináceas, para produzir uma fração enriquecida em uma molécula proteinácea, e para fracionar uma mistura que contém moléculas proteináceas, fração, e, usos de uma fração ou composição, e de eritropoietina recombinantemente produzìvel em uma célula de mamìfero |
NZ533124A (en) | 2001-12-07 | 2005-11-25 | Crucell Holland B | Production of viruses, viral isolates and vaccines |
US8524477B2 (en) * | 2002-10-29 | 2013-09-03 | Crucell Holland B.V. | Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby |
WO2005090390A1 (en) * | 2004-03-17 | 2005-09-29 | Crucell Holland B.V. | Novel assay for the separation and quantification of hemagglutinin antigens |
WO2006079155A1 (en) * | 2005-01-25 | 2006-08-03 | Apollo Life Sciences Limited | Molecules and chimeric molecules thereof |
US20100040581A1 (en) * | 2005-06-01 | 2010-02-18 | Niigata Tlo Corporation | Epo derivative-containing therapeutic agents for blood-related diseases |
AR053416A1 (es) * | 2005-11-10 | 2007-05-09 | Protech Pharma S A | Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac |
CA2628725A1 (en) * | 2005-11-15 | 2007-05-31 | Glycofi, Inc. | Production of glycoproteins with reduced o-glycosylation |
US7642078B2 (en) | 2005-12-28 | 2010-01-05 | Crucell Holland B.V. | Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby |
US10221228B2 (en) | 2006-02-03 | 2019-03-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US20150038413A1 (en) | 2006-02-03 | 2015-02-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US10351615B2 (en) | 2006-02-03 | 2019-07-16 | Opko Biologics Ltd. | Methods of treatment with long-acting growth hormone |
US8048849B2 (en) | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
US20140113860A1 (en) | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
US9249407B2 (en) | 2006-02-03 | 2016-02-02 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US7553941B2 (en) * | 2006-02-03 | 2009-06-30 | Modigene Inc | Long-acting polypeptides and methods of producing same |
US8946155B2 (en) | 2006-02-03 | 2015-02-03 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
WO2007098548A1 (en) * | 2006-03-01 | 2007-09-07 | Apollo Life Sciences Limited | A molecule and chimeric molecules thereof |
CN101460188B (zh) | 2006-06-07 | 2013-09-04 | 国立大学法人德岛大学 | 使用促红细胞生成素的局部缺血疾病的治疗 |
JPWO2008023725A1 (ja) | 2006-08-22 | 2010-01-14 | 中外製薬株式会社 | 末梢神経障害の予防および/または治療剤 |
AR065613A1 (es) | 2007-03-09 | 2009-06-17 | Chugai Pharmaceutical Co Ltd | Agentes de proteccion para organos transplantados |
BRPI0810065A2 (pt) | 2007-04-16 | 2020-01-14 | Momenta Pharmaceuticals Inc | caracterização de n-glicanos usando exoglicosidases |
TWI488640B (zh) | 2008-04-16 | 2015-06-21 | Ferring Int Ct Sa | 藥學製劑 |
US8138092B2 (en) | 2009-01-09 | 2012-03-20 | Lam Research Corporation | Spacer formation for array double patterning |
US9663778B2 (en) | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
TWI604850B (zh) * | 2009-10-05 | 2017-11-11 | 菲瑞茵國際中心股份有限公司 | 藥學製劑 |
EP2691119B1 (en) | 2011-03-31 | 2018-08-01 | Ferring B.V. | Pharmaceutical preparation |
WO2013067322A1 (en) * | 2011-11-03 | 2013-05-10 | Stc Biologics, Inc. | Method for determination of pharmacological properties of recombinant proteins |
WO2013157002A1 (en) | 2012-04-19 | 2013-10-24 | Prolor Biotech Inc. | Long-acting oxyntomodulin variants and methods of producing same |
CN112661863A (zh) | 2012-11-20 | 2021-04-16 | 奥普科生物制品有限公司 | 通过连接至促性腺激素羧基端肽来增加多肽的流体动力学体积的方法 |
US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
WO2016004242A1 (en) * | 2014-07-01 | 2016-01-07 | Stc Biologics, Inc. | A method for development of recombinant proteins with fingerprint like similarity to the reference product |
EP3988113A1 (en) | 2015-06-19 | 2022-04-27 | OPKO Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
BR112019000610A2 (pt) | 2016-07-11 | 2019-07-02 | Opko Biologics Ltd | fator vii de coagulação de longa ação e métodos de produção do mesmo |
KR20230048469A (ko) * | 2016-07-12 | 2023-04-11 | 헥살 아게 | 시알산 잔기의 감소된 아세틸화율을 갖는 당단백질 |
WO2019075053A1 (en) * | 2017-10-11 | 2019-04-18 | Elanco Us Inc. | PORCINE G-CSF VARIANTS AND USES THEREOF |
CN111514279B (zh) * | 2020-06-16 | 2023-07-18 | 温州医科大学附属第二医院(温州医科大学附属育英儿童医院) | 神经营养因子3在制备治疗男性性腺功能减退症的药物中的应用 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991005867A1 (en) | 1989-10-13 | 1991-05-02 | Amgen Inc. | Erythropoietin isoforms |
US5789247A (en) * | 1994-04-01 | 1998-08-04 | Ballay; Annick | Expression in non-tumoral human lymphoblastoid lines with an integrative vector |
US6783980B2 (en) * | 1995-06-15 | 2004-08-31 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
JP4051416B2 (ja) | 1995-06-15 | 2008-02-27 | クルーセル ホランド ベスローテン フェンノートシャップ | 遺伝子治療に使用されるヒト組換えアデノウイルス用のパッケージングシステム |
CA2221819A1 (en) * | 1997-03-27 | 1998-09-27 | Thomas A. Gigliatti | Insect expression vectors |
ATE290091T1 (de) * | 1997-03-27 | 2005-03-15 | Univ British Columbia | Insekten-expressionsvektoren |
US6929946B1 (en) * | 1998-11-20 | 2005-08-16 | Crucell Holland B.V. | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells |
CN1607957B (zh) | 1999-04-13 | 2012-10-10 | 肯尼思S.沃伦协会有限公司 | 外周给药的红细胞生成素对应激组织功能的调制 |
US7297680B2 (en) * | 1999-04-15 | 2007-11-20 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
US20050164386A1 (en) * | 1999-04-15 | 2005-07-28 | Uytdehaag Alphonsus G. | Overexpression of enzymes involved in post-translational protein modifications in human cells |
US6855544B1 (en) * | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
ATE536417T1 (de) * | 1999-04-15 | 2011-12-15 | Crucell Holland Bv | Herstellung von rekombinanten proteinen in einer menschlichen zelle mit mindestens einem e1 adenovirus protein |
US6913922B1 (en) * | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
FI109811B (fi) * | 2000-09-26 | 2002-10-15 | Medicel Oy | Menetelmä GDP-L-fukoosin valmistamiseksi ja menetelmässä käytettäviä välineitä |
DE10056136A1 (de) | 2000-11-07 | 2002-05-16 | Nemod New Modalities | Verwendung von Schwangerschaftsproteinen, Liposomen, nativen Muzin-Fragmenten und Mimikry-Verbindungen zur Behandlung und Prophylaxe von entzündlichen Erkrankungen, zur Verhinderung der Metastasierung und zur Prophylaxe von Tumorerkrankungen |
US7473767B2 (en) | 2001-07-03 | 2009-01-06 | The Institute For Systems Biology | Methods for detection and quantification of analytes in complex mixtures |
EP2292271A3 (en) * | 2001-10-10 | 2011-09-14 | BioGeneriX AG | Remodelling and glycoconjugation of an antibody |
BR0213402A (pt) * | 2001-10-29 | 2004-10-13 | Crucell Holland Bv | Métodos para identificar uma célula de mamìfero capaz de produzir uma molécula proteinácea, para selecionar uma célula de mamìfero capaz de produzir uma molécula proteinácea, para se obter uma célula de mamìfero a partir de uma população heterogênea de células, e para produzir uma molécula proteinácea, composição farmaceuticamente aceitável, eritropoietina recombinantemente produzida, usos de uma célula de mamìfero, da eritropoietina recombinantemente produzida, e de uma composição de moléculas semelhantes à eritropoietina, preparação farmacêutica, método para o tratamento preventivo e/ou terapêutico de um distúrbio, composição de moléculas semelhates à eritropoietina, métodos para produzir, em uma célula de mamìfero, moléculas proteináceas, para produzir uma fração enriquecida em uma molécula proteinácea, e para fracionar uma mistura que contém moléculas proteináceas, fração, e, usos de uma fração ou composição, e de eritropoietina recombinantemente produzìvel em uma célula de mamìfero |
ES2368733T3 (es) * | 2002-07-18 | 2011-11-21 | Merus B.V. | Producción recombinante de mezclas de anticuerpos. |
WO2005090390A1 (en) * | 2004-03-17 | 2005-09-29 | Crucell Holland B.V. | Novel assay for the separation and quantification of hemagglutinin antigens |
US7183371B2 (en) * | 2004-11-01 | 2007-02-27 | General Electric Company | Method for making polycarbonate |
US20080139608A1 (en) * | 2006-12-06 | 2008-06-12 | Universiteit Leiden | 2,6,8, Trisubstituted 1-deazapurines and their different uses |
-
2002
- 2002-10-29 BR BR0213402-0A patent/BR0213402A/pt not_active IP Right Cessation
- 2002-10-29 EA EA200400605A patent/EA008220B1/ru not_active IP Right Cessation
- 2002-10-29 WO PCT/NL2002/000686 patent/WO2003038100A1/en active Application Filing
- 2002-10-29 EP EP10177590.6A patent/EP2292770B1/en not_active Expired - Lifetime
- 2002-10-29 ES ES02770322T patent/ES2381104T3/es not_active Expired - Lifetime
- 2002-10-29 AT AT02770322T patent/ATE542904T1/de active
- 2002-10-29 DK DK02770322.2T patent/DK1440157T3/da active
- 2002-10-29 CA CA2465007A patent/CA2465007C/en not_active Expired - Fee Related
- 2002-10-29 EA EA200602163A patent/EA012340B1/ru not_active IP Right Cessation
- 2002-10-29 CA CA2756610A patent/CA2756610C/en not_active Expired - Fee Related
- 2002-10-29 EP EP02770322A patent/EP1440157B1/en not_active Expired - Lifetime
- 2002-10-29 AU AU2002335585A patent/AU2002335585B2/en not_active Ceased
- 2002-10-29 US US10/494,140 patent/US7304031B2/en not_active Expired - Fee Related
- 2002-10-29 JP JP2003540365A patent/JP4583029B2/ja not_active Expired - Fee Related
- 2002-10-29 CN CNB028216903A patent/CN100347306C/zh not_active Expired - Fee Related
-
2004
- 2004-04-29 IL IL161674A patent/IL161674A/en not_active IP Right Cessation
- 2004-05-28 NO NO20042209A patent/NO20042209L/no not_active Application Discontinuation
-
2007
- 2007-01-24 US US11/657,202 patent/US7785833B2/en not_active Expired - Fee Related
- 2007-08-01 US US11/888,776 patent/US7696157B2/en not_active Expired - Fee Related
-
2009
- 2009-10-21 IL IL201673A patent/IL201673A/en not_active IP Right Cessation
- 2009-10-21 IL IL201674A patent/IL201674A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP1440157B1 (en) | 2012-01-25 |
CN1578838A (zh) | 2005-02-09 |
AU2002335585B2 (en) | 2007-08-16 |
CA2756610A1 (en) | 2003-05-08 |
EP2292770A2 (en) | 2011-03-09 |
US7785833B2 (en) | 2010-08-31 |
EP2292770B1 (en) | 2014-11-26 |
US7696157B2 (en) | 2010-04-13 |
BR0213402A (pt) | 2004-10-13 |
ATE542904T1 (de) | 2012-02-15 |
ES2381104T3 (es) | 2012-05-23 |
JP2005507426A (ja) | 2005-03-17 |
JP4583029B2 (ja) | 2010-11-17 |
CA2465007A1 (en) | 2003-05-08 |
US20050164917A1 (en) | 2005-07-28 |
US20070117742A1 (en) | 2007-05-24 |
CN100347306C (zh) | 2007-11-07 |
WO2003038100A1 (en) | 2003-05-08 |
EA200400605A1 (ru) | 2004-08-26 |
IL161674A (en) | 2014-06-30 |
EP2292770A3 (en) | 2012-12-19 |
EA008220B1 (ru) | 2007-04-27 |
EA200602163A1 (ru) | 2007-04-27 |
CA2465007C (en) | 2012-01-17 |
IL201673A (en) | 2013-10-31 |
US7304031B2 (en) | 2007-12-04 |
EP1440157A1 (en) | 2004-07-28 |
US20080032922A1 (en) | 2008-02-07 |
DK1440157T3 (da) | 2012-05-07 |
IL201674A (en) | 2013-10-31 |
EA012340B1 (ru) | 2009-10-30 |
CA2756610C (en) | 2015-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20042209L (no) | Fremgangsmater og anordninger for fremstilling av proteiner med forutbestemte post-translasjonelle modifikasjoner | |
DE59608743D1 (de) | Verfahren zur herstellung von rekombinanten proteinen in e. coli mittels hochzelldichte-fermentation | |
DE68921364D1 (de) | Verfahren zur Herstellung von Proteinen mittels rekombinanter DNA. | |
ATE475714T1 (de) | Verfahren zur herstellung von glycoprotein mit menschlichem glycosylierungsbild | |
DE69434578D1 (de) | Expressionsvektoren die für bispezifische Proteine kodieren, und Verfahren zur Herstellung von biologisch-aktiven bispezifischen Fusionsproteine in Zellen von Säugertieren | |
ATE140960T1 (de) | Verfahren zur herstellung von zellen, die stabil integrierte fremde dns mit hoher kopiezahl enthalten, durch dieses verfahren hergestellte zellen und verwendung dieser zellen zur herstellung von durch diese fremde dns kodierten polypeptiden | |
DK0939767T3 (da) | Procin faktor VIII og hybrider deraf | |
ATE397752T1 (de) | Verfahren und verwendung von anordungen von proteinfixierungsmitteln | |
ATE294229T1 (de) | Verfahren zur trocknung von kompetenten zellen | |
HUP0103414A2 (hu) | Amiloszacharázt kódoló nukleinsav molekulák | |
DE3486179T2 (de) | Verfahren zur herstellung vielkettige polypeptide oder proteine. | |
DE60042122D1 (de) | Fibroblasten wachstumsfaktor-ähnliche polypeptide | |
ATE500331T1 (de) | Verfahren zur gleichzeitigen herstellung von multiplen proteinen; vektoren und zellen, die hierfür verwendung finden | |
NO911688L (no) | Neurotrophin-3, en ny neurotrofisk faktor relatert til neurovekstfaktor og hjerne-avledet neurotrofisk faktor. | |
KR910004803A (ko) | 간의 실질 세포 성장 인자, 이를 코딩하는 유전자, 이 인자를 생산하는 방법, 및 이 인자를 생산하는 형질전환체 | |
DE69632887D1 (de) | Verfahren zur zweckmässige Herstellung von Transglutaminase durch DNA-Rekombination | |
DE69939268D1 (de) | Methoden zur aufreinigung von rekombinatem humanem erythropoietin aus zellkulturüberständen | |
DK0963377T3 (da) | Interleukin-19 | |
ATE433486T1 (de) | Durchmusterung von bibliotheken exprimierter dna in filamentösen pilzen mit hoher durchsatzrate | |
DE60211772D1 (de) | Verfahren zur Herstellung von Proteine | |
DE69430975D1 (de) | Verfahren zur Herstellung von Proteinen | |
DE69425809T2 (de) | Methoden zur Herstellung von Protein C | |
ATE435277T1 (de) | 18477, eine menschliche proteinkinase und deren verwendung | |
ATA127399A (de) | Verfahren zur modifizierung von polymeroberflächen | |
DE69530261D1 (de) | Durch Zelldichte stimulierte Protein-Tyrosin-Phosphatasen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |